PRLD Stock Summary and Trading Ideas (Prelude Therapeutics | NASDAQ:PRLD)

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Prelude Therapeutics trades on the NASDAQ stock market under the symbol PRLD.

As of November 3, 2026, PRLD stock price climbed to $3.87 with 651 million shares trading.

PRLD has a beta of 1.65, meaning it tends to be more sensitive to market movements. PRLD has a correlation of 0.04 to the broad based SPY ETF.

PRLD has a market cap of $308.84 million. This is considered a Small Cap stock.

In the last 3 years, PRLD traded as high as $6.83 and as low as $.61.

The top ETF exchange traded funds that PRLD belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

PRLD has outperformed the market in the last year with a price return of +143.4% while the SPY ETF gained +11.5%. However, in the short term, PRLD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.9% vs +1.1% return in SPY. But in the last 2 weeks, PRLD shares have fared better than the market returning +14.2% compared to SPY -1.7%.

PRLD support price is $3.66 and resistance is $4.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRLD shares will trade within this expected range on the day.